Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board -- Ignore unavailable to you. Want to Upgrade?

To: PoorOpinion who wrote (1566)	4/6/2016 4:26:33 AM
From: Dave@SI	Respond to of 1728

There has just been an update posted on a Springer hosted status page for the current trial. See the new entry for 29th March, which seems to be a simplified restatement of the original Nov 2015 approval. No idea what this means. Just a clerical glitch? Possibly some minor detail change? Some inclusion of BriaDiag?

To: PoorOpinion who wrote (1566)	4/7/2016 5:46:09 AM
From: Dave@SI	Respond to of 1728

Based on this just-published Jason Napodano BioNap paid-for article's unofficial 'hints' (ie his, err, "guesses") re newsflow, costings, raises: 1) CRO Partner announcement is imminent. [Well it better had be I guess.] 2) There will be interim results after 4-6 months for an initial 8-10 patients. [What evidence do we have for this? See below.] 3) Either they have enough cash, $0.5m, for the initial patients, or will do a small "bridge financing" to cover it. 4) They will do a raise for the rest of the patients ($2-3m total trial cost) after the interim results. In the 2015-08-11 BioTuesday article, there was mention of "interim results", but that was very non-specific and could even have meant the end of the planned I/IIa study as in interim to the next trial. I don't think there has been any other interim results reference. The funding points make good sense to me in that I think BCT have implied that they are cashed-up to start but not complete the trial. Not mentioned in this article but mooted previously by the company is that grants are available once the trial starts.